Biopharma IPOs From the First Half of 2024

At the end of 2023, PwC predicted a “gradual uptick” in IPOs, with the market expected to favor those companies with “strong clinical data.” Roel van den Akker, pharmaceutical and life sciences deals leader at PwC, said that current market activity aligns with the firm’s predictions.